Innovative Cryopreservation Evia Bio specializes in non-DMSO cryopreservation solutions that preserve cell integrity during storage, making them highly attractive for cell therapy companies seeking safer, more effective preservation methods to enhance product stability and patient safety.

Growing Market Focus With recent launches targeting induced pluripotent stem cells and cell and gene therapies, Evia Bio is positioning itself to serve the expanding regenerative medicine and personalized therapy markets, offering integrative cryopreservation solutions.

Research Backing Led by prominent cryobiologist Allison Hubel, the company's solutions are backed by scientific expertise, providing a compelling value proposition for biotech firms investing in innovation and reliable, science-based technology.

Strategic Partnerships Evia Bio actively collaborates with cell therapy developers aiming to advance their products into clinical trials, representing a direct opportunity to engage with pipeline-stage companies seeking specialized cryopreservation solutions.

Market Entry Potential Despite current revenue levels, Evia Bio’s recent product launches and technological innovations present significant growth opportunities, making it an ideal partner for firms looking to strengthen their cell storage capabilities and accelerate market entry.